Within Subject, Dose-Escalation Trial of Continuously Infused Intraputamental (Ipu) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Subjects with Idiopathic Parkinson's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date5/23/029/30/09

Funding

  • AMGen: $824,512.00